Cargando…

Combination strategies to overcome drug resistance in FLT(+) acute myeloid leukaemia

BACKGROUND: Acute myeloid leukaemia (AML) remains difficult to treat despite the development of novel formulations and targeted therapies. Activating mutations in the FLT3 gene are common among patients and make the tumour susceptible to FLT3 inhibitors, but resistance to such inhibitors develops qu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Jingmei, Friedman, Ran
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10416533/ https://www.ncbi.nlm.nih.gov/pubmed/37568211 http://dx.doi.org/10.1186/s12935-023-03000-x

Ejemplares similares

Combating drug resistance in acute myeloid leukaemia by drug rotations: the effects of quizartinib and pexidartinib
por: Yang, Jingmei, et al.
Publicado: (2021)

Targeting C/EBPα overcomes primary resistance and improves the efficacy of FLT3 inhibitors in acute myeloid leukaemia
por: Wang, Hanlin, et al.
Publicado: (2023)

Computer simulations of the signalling network in FLT3 (+)-acute myeloid leukaemia – indications for an optimal dosage of inhibitors against FLT3 and CDK6
por: Buetti-Dinh, Antoine, et al.
Publicado: (2018)

GNF-7, a novel FLT3 inhibitor, overcomes drug resistance for the treatment of FLT3‑ITD acute myeloid leukemia
por: Xiao, Xinhua, et al.
Publicado: (2023)

A dual inhibitor overcomes drug-resistant FLT3-ITD acute myeloid leukemia
por: Wang, Peihong, et al.
Publicado: (2021)

Targeting enhancer switching overcomes non-genetic drug resistance in acute myeloid leukaemia
por: Bell, Charles C., et al.
Publicado: (2019)

The effects of combination treatments on drug resistance in chronic myeloid leukaemia: an evaluation of the tyrosine kinase inhibitors axitinib and asciminib
por: G. Lindström, H. Jonathan, et al.
Publicado: (2020)

Identification of FLT3 and NPM1 Mutations in Patients with Acute Myeloid Leukaemia
por: Yusoff, Yuslina Mat, et al.
Publicado: (2019)

Sitravatinib as a potent FLT3 inhibitor can overcome gilteritinib resistance in acute myeloid leukemia
por: Zhang, Yvyin, et al.
Publicado: (2023)

Novel AXL-targeted agents overcome FLT3 inhibitor resistance in FLT3-ITD(+) acute myeloid leukemia cells
por: Liu, Yi, et al.
Publicado: (2021)

Concomitant targeting of FLT3 and BTK overcomes FLT3 inhibitor resistance in acute myeloid leukemia through the inhibition of autophagy
por: Zhang, Weiguo, et al.
Publicado: (2022)

Oncogenic roles of PRL-3 in FLT3-ITD induced acute myeloid leukaemia
por: Park, Jung Eun, et al.
Publicado: (2013)

FLT3‐ITD mutations in acute myeloid leukaemia – molecular characteristics, distribution and numerical variation
por: Engen, Caroline, et al.
Publicado: (2021)

A Combined Histone Deacetylases Targeting Strategy to Overcome Venetoclax Plus Azacitidine Regimen Resistance in Acute Myeloid Leukaemia: Three Case Reports
por: Wang, Bin-Ru, et al.
Publicado: (2021)

Flt3-ITD mutations in a mouse model of radiation-induced acute myeloid leukaemia
por: Finnon, R, et al.
Publicado: (2012)

Clinical and molecular features of FLT3 juxtamembrane domain missense mutations in acute myeloid leukaemia
por: Jensen, Christopher E., et al.
Publicado: (2022)

Sex disparity in acute myeloid leukaemia with FLT3 internal tandem duplication mutations: implications for prognosis
por: Hellesøy, Monica, et al.
Publicado: (2021)

A novel approach for relapsed/refractory FLT3(mut+) acute myeloid leukaemia: synergistic effect of the combination of bispecific FLT3scFv/NKG2D-CAR T cells and gilteritinib
por: Li, Ke-xin, et al.
Publicado: (2022)

FLT3‐targeted therapy restores GATA1 pathway function in NPM1/FLT3‐ITD mutated acute myeloid leukaemia
por: Sorcini, D, et al.
Publicado: (2023)

Quantitative phosphoproteomics uncovers synergy between DNA-PK and FLT3 inhibitors in acute myeloid leukaemia
por: Murray, Heather C., et al.
Publicado: (2020)

Therapeutic targeting of FLT3 and associated drug resistance in acute myeloid leukemia
por: Gebru, Melat T., et al.
Publicado: (2020)

Selective FLT3 inhibition of FLT3-ITD(+) acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patterns
por: Moore, Andrew S., et al.
Publicado: (2012)

Overcoming Resistance to FLT3 Inhibitors in the Treatment of FLT3-Mutated AML
por: Lam, Stephen S.Y., et al.
Publicado: (2020)

Resistance to FLT3 inhibitors in acute myeloid leukemia: Molecular mechanisms and resensitizing strategies
por: Zhou, Jianbiao, et al.
Publicado: (2018)

Autophagy activation mediates resistance to FLT3 inhibitors in acute myeloid leukemia with FLT3-ITD mutation
por: Xu, Dan, et al.
Publicado: (2022)

Clinico-Haematologic association and prognostic relevance of NPM1 and FLT3-ITD mutations in acute Myeloid Leukaemia
por: Mahmood, Rafia, et al.
Publicado: (2019)

HSP70 and FLT3-ITD: Targeting chaperone system to overcome drug resistance
por: Yang, Jing, et al.
Publicado: (2021)

Dual inhibition of AKT/FLT3-ITD by A674563 overcomes FLT3 ligand-induced drug resistance in FLT3-ITD positive AML
por: Wang, Aoli, et al.
Publicado: (2016)

Overcoming myelosuppression due to synthetic lethal toxicity for FLT3-targeted acute myeloid leukemia therapy
por: Warkentin, Alexander A, et al.
Publicado: (2014)

Correction: A novel approach for relapsed/refractory FLT3(mut+)acute myeloid leukaemia: synergistic effect of the combination of bispecific FLT3scFv/NKG2D-CAR T cells and gilteritinib
por: Li, Ke-xin, et al.
Publicado: (2022)

Practical Considerations for Treatment of Relapsed/Refractory FLT3-ITD Acute Myeloid Leukaemia with Quizartinib: Illustrative Case Reports
por: Martínez-Cuadrón, David, et al.
Publicado: (2020)

A novel small molecule RAD51 inactivator overcomes imatinib-resistance in chronic myeloid leukaemia
por: Zhu, Jiewen, et al.
Publicado: (2013)

Modulation of FLT3-ITD Localization and Targeting of Distinct Downstream Signaling Pathways as Potential Strategies to Overcome FLT3-Inhibitor Resistance
por: Fleischmann, Maximilian, et al.
Publicado: (2021)

Targeting Oncoprotein Stability Overcomes Drug Resistance Caused by FLT3 Kinase Domain Mutations
por: Yu, Chuanjiang, et al.
Publicado: (2014)

Combined inhibition of Notch and FLT3 produces synergistic cytotoxic effects in FLT3/ITD(+) acute myeloid leukemia
por: Li, Dan, et al.
Publicado: (2020)

A novel combination regimen of BET and FLT3 inhibition for FLT3-ITD acute myeloid leukemia
por: Lee, Lauren Y., et al.
Publicado: (2021)

A novel approach to overcome drug resistance in acute myeloid leukemia
por: Mazewski, Candice, et al.
Publicado: (2023)

Acute Myeloid Leukaemia in Its Niche: the Bone Marrow Microenvironment in Acute Myeloid Leukaemia
por: Ladikou, E. E., et al.
Publicado: (2020)

PB1779: DEVELOPING NOVEL SYNERGISTIC DRUG COMBINATIONS WITH VENETOCLAX IN ACUTE MYELOID LEUKAEMIA
por: Harrigan, R., et al.
Publicado: (2022)

Mechanisms of Resistance and Implications for Treatment Strategies in Chronic Myeloid Leukaemia
por: Poudel, Govinda, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_sllqe51g5ht9urirnaece2gu2r